Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 70,12 € (-0,04 %). Medianen er 70,28 € (+0,19 %).

Køb	11
Behold	6
Sælg	0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Tempus AI posts strong Q3 results — stock rises, analysts raise price targets

Tempus AI reported strong third-quarter results; the stock rose about 8.7% on the Nasdaq. BTIG raised its price target to $100 with a "Buy" rating, Needham reiterated the buy recommendation with a $89 target, and Jefferies removed its sell rating and now rates the stock "Hold" at $70. The data business remains the strongest revenue driver, and the planned acquisition of Personalis could add further growth. » Mere på deraktionaer.de
Tempus AI beats expectations and raises full-year revenue guidance slightly

Tempus AI reported Q3 revenue up 23% to $411.5 million, beating analysts’ estimates. Adjusted EBITDA was $25.6 million and earnings per share were $0.07 instead of the expected loss of $0.07. The company raised the lower end of its full-year revenue guidance to $1.60 billion; adjusted EBITDA remains around $65 million. The stock rose just over 4% in premarket trading. » Mere på deraktionaer.de
Tempus AI jumps about 15% to a year high

The stock of Tempus AI climbed nearly 15% to $80.36, reaching a new year high. Market participants view this as a reaction to the company’s growth potential, the acquisition of Personalis, and comments by Eric Lefkofsky on AI in healthcare. Technically, the breakout above the August high on heavy volume delivered a clear buy signal, and analysts had already issued buy recommendations. Tempus AI benefits from its growing dataset for personalized medicine, which is expected to gain importance over the long term. » Mere på deraktionaer.de
Tempus AI jumps after Morgan Stanley flags $330M–$400M reimbursement upside

Tempus AI shares surged about 30% this week after Morgan Stanley highlighted reimbursement pricing that could add $330 million to $400 million in annual revenue from xT and xF diagnostics. CEO Eric Lefkofsky said the company should exceed its 25% multiyear growth target, citing roughly $200 million in Q2 data licensing bookings from AstraZeneca, GSK and Merck. Management raised FY guidance and reiterated a path to positive free cash flow, though the stock still trades below its 52-week high and carries high beta and ongoing GAAP losses. » Mere på finance.yahoo.com
Tempus AI rises sharply after remarks on AI benefits in healthcare

Tempus AI's stock climbed about ten percent on Tuesday after founder and CEO Eric Lefkofsky emphasized that healthcare is likely to benefit most from AI. Tempus combines diagnostics and data services and uses extensive datasets and large AI models to improve diagnostics and help pharma companies develop drugs. The company has a market capitalization of roughly $12 billion and is aiming to grow in precision oncology with the planned acquisition of Personalis; a break above the August high would open up further upside potential. » Mere på deraktionaer.de

Virksomhedstal

I det seneste kvartal havde Tempus AI en omsætning på 363,33 mio. € og et nettoresultat på -13,11 mio. €

(EUR)	september 2026	YoY
Omsætning	363,33 mio.	27,58 %
Bruttofortjeneste	235,46 mio.	31,62 %
Nettoresultat	-13,11 mio.	80,76 %
EBITDA	18,08 mio.	154,71 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	12,69 mia. €
Antal aktier	177,36 mio.
Højeste/laveste i 52 uger	80,27 € - 36,73 €
Udbytte	Nej
Beta	3,61
P/E (PE Ratio)	-75,65
PEG (PEG Ratio)	13,81
K/I (PB Ratio)	28,78
P/S (PS Ratio)	9,33

Virksomhedsprofil

Tempus AI, Inc driver virksomhed inden for sundhedsteknologi. Selskabet leverer next generation sequencing-diagnostik, polymerase chain reaction-profilering, molekylær genotypning og anden anatomisk og molekylær patologisk testning til sundhedsudbydere, farmaceutiske virksomheder, bioteknologiske virksomheder, forskere og andre tredjeparter. Selskabet tilbyder desuden Insights, et licensbibliotek med koblede kliniske, molekylære og billeddiagnostiske de-identificerede data, samt en pakke analytiske tjenester og analyse- og cloud-og-compute-værktøjer til farmaceutiske og bioteknologiske virksomheder; og Trials, som leverer matchning af kliniske forsøg til farmaceutiske virksomheder. Derudover driver selskabet Next; Algos, en pakke algoritmiske tests inden for onkologi; Hub, en desktop- og mobilplatform til bestilling, håndtering og modtagelse af tests og patientresultater; og Lens, en platform, hvor forskere og videnskabsfolk kan finde, få adgang til og analysere Tempus-data. Selskabet var tidligere kendt som Tempus Labs, Inc og ændrede navn til Tempus AI, Inc i januar 2023. Tempus AI, Inc blev stiftet i 2015 og har hovedkontor i Chicago, Illinois.